Debiopharm Revenue and Competitors
Estimated Revenue & Valuation
- Debiopharm's estimated annual revenue is currently $98.8M per year.
- Debiopharm's estimated revenue per employee is $162,500
Employee Data
- Debiopharm has 608 Employees.
- Debiopharm grew their employee count by 5% last year.
Debiopharm Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 26 | -4% | $15.7M | N/A |
#2 | $24.7M | 173 | 9% | N/A | N/A |
#3 | $1.4M | 21 | -50% | $21.2M | N/A |
#4 | $41.9M | 293 | 8% | $6M | N/A |
#5 | $6M | 53 | -22% | $216.8M | N/A |
#6 | $0M | 2 | 0% | $33.3M | N/A |
#7 | $26M | 182 | 0% | N/A | N/A |
#8 | $30.9M | 221 | -26% | $64.6M | N/A |
#9 | $28.6M | 205 | -22% | $46.8M | N/A |
#10 | $249.1M | 1340 | 15% | $75M | N/A |
What Is Debiopharm?
Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe. Debiopharm International SA focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. Debiopharm completed the development and licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If you have interesting molecules and seek a competent and committed partner to develop them, please contact us.
keywords:N/AN/A
Total Funding
608
Number of Employees
$98.8M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Debiopharm's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Investment Principal - Debiopharm Innovation Fund | Reveal Email/Phone |
3 | Senior Global Manager Pricing & HEOR | Reveal Email/Phone |
4 | Directeur Administration et Ressources Humaines | Reveal Email/Phone |
5 | Directeur associé service technique | Reveal Email/Phone |
6 | Biostatics Project Lead | Reveal Email/Phone |
7 | Head Medicinal Chemistry | Reveal Email/Phone |
8 | Assistante Achats & Voyages | Reveal Email/Phone |
9 | Analytical Project Manager | Reveal Email/Phone |
10 | Informaticien | Reveal Email/Phone |
Debiopharm News
AbbVie, Astellas Pharma, AstraZeneca, Debiopharm Group, Evotec AG, Kissei Pharmaceutical, Neurocrine Biosciences, ObsEva, Pfizer,...
DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES. USA - English. USA -...
Debiopharm develops, manufactures and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $630.9M | 2146 | 3% | N/A |
#2 | $1383.3M | 4066 | 5% | N/A |
#3 | $1471.5M | 7321 | 5% | N/A |
#4 | $5008.2M | 15690 | 12% | N/A |